Physician profile
Jeffrey A Marcus
NPI 1851393482
$12,236.69
in general payments reported to CMS, 2019-2025
38 companies · $613 in 2025
The $613 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $340 · 2021: $589 · 2022: $9,318 · 2023: $463 · 2024: $459 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| C2dx, INC | $8,500.00 | 2022 | |
| Abbvie INC. | $773.06 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $570.69 | 2019-2025 | |
| Astellas Pharma US INC | $224.31 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $218.71 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $185.95 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $176.72 | 2019-2023 | Slynd |
| Organon LLC | $171.75 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $157.05 | 2022-2025 | |
| Myovant Sciences INC. | $120.68 | 2021-2022 | |
| Avion Pharmaceuticals | $119.42 | 2019-2022 | |
| Roche Diagnostics Corporation | $101.33 | 2019-2020 | |
| Amgen INC. | $87.15 | 2019-2020 | |
| Agile Therapeutics, INC. | $86.45 | 2021-2022 | |
| Optumhealth Care Solutions, LLC | $65.03 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $59.86 | 2019-2022 | |
| Duchesnay USA Incorporated | $46.01 | 2019 | |
| Millicent US INC | $44.59 | 2024-2025 | Femlyv, Intrarosa |
| Biohaven Pharmaceutical Holding Company LTD. | $42.39 | 2022 | |
| Coloplast Corp | $37.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.89 | 2021 | |
| Channel Medsystems, INC. | $36.78 | 2025 | |
| Ascend Therapeutics US, LLC | $36.00 | 2021 | |
| Hologic Sales and Service, LLC | $34.40 | 2021-2023 | Aptima |
| Eisai INC. | $33.61 | 2020 | |
| Evofem Biosciences, INC. | $33.13 | 2022 | |
| Biogen, INC. | $28.72 | 2024 | Zurzuvae |
| Allergan, INC. | $28.52 | 2019 | |
| Novo Nordisk INC | $28.37 | 2023-2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $23.17 | 2023 | Quviviq |
| Mission Pharmacal Company | $18.59 | 2019 | |
| Smith+Nephew, INC. | $18.33 | 2023 | Pico 14, Pico 7, Renasys Go V2 Home |
| Alydia Health | $18.22 | 2021 | |
| Scynexis, INC. | $17.71 | 2022 | |
| Merck Sharp & Dohme LLC | $16.76 | 2024 | Gardasil, Gardasil 9 |
| Exact Sciences Corporation | $15.24 | 2025 | Cologuard Collection Kit |
| Coopersurgical, INC. | $15.22 | 2025 | |
| Meditrina | $7.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.